Show simple item record

dc.contributor.authorKulkarni, Chethana
dc.contributor.authorBetts, Alison M.
dc.contributor.authorMaass, Katie F.
dc.contributor.authorQuadir, Mohiuddin Abdul
dc.contributor.authorHammond, Paula T.
dc.contributor.authorWittrup, Karl Dane
dc.date.accessioned2017-02-21T17:05:29Z
dc.date.available2017-02-21T17:05:29Z
dc.date.issued2016-01
dc.date.submitted2015-07
dc.identifier.issn0022-3549
dc.identifier.issn1520-6017
dc.identifier.urihttp://hdl.handle.net/1721.1/107005
dc.description.abstractStandard cell proliferation assays use bulk media drug concentration to ascertain the potency of chemotherapeutic drugs; however, the relevant quantity is clearly the amount of drug actually taken up by the cell. To address this discrepancy, we have developed a flow cytometric clonogenic assay to correlate the amount of drug in a single cell with the cell’s ability to proliferate using a cell tracing dye and doxorubicin, a naturally fluorescent chemotherapeutic drug. By varying doxorubicin concentration in the media, length of treatment time, and treatment with verapamil, an efflux pump inhibitor, we introduced 10[superscript 5]–10[superscript 10] doxorubicin molecules per cell; then used a dye-dilution assay to simultaneously assess the number of cell divisions. We find that a cell’s ability to proliferate is a surprisingly conserved function of the number of intracellular doxorubicin molecules, resulting in single-cell IC[subscript 50] values of 4–12 million intracellular doxorubicin molecules. The developed assay is a straightforward method for understanding a drug’s single-cell potency and can be used for any fluorescent or fluorescently labeled drug, including nanoparticles or antibody–drug conjugates.en_US
dc.description.sponsorshipHertz Foundation (Fellowship)en_US
dc.description.sponsorshipNational Science Foundation (U.S.). Graduate Research Fellowship Programen_US
dc.description.sponsorshipPfizer Inc.en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (David H. Koch Institute for Integrative Cancer Research at MIT. Support (Core) Grant P30-CA14051)en_US
dc.language.isoen_US
dc.publisherWiley Blackwellen_US
dc.relation.isversionofhttp://dx.doi.org/10.1002/jps.24631en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleA Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicinen_US
dc.typeArticleen_US
dc.identifier.citationMaass, Katie F. et al. “A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.” Journal of Pharmaceutical Sciences 104.12 (2015): 4409–4416.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorMaass, Katie F.
dc.contributor.mitauthorQuadir, Mohiuddin Abdul
dc.contributor.mitauthorHammond, Paula T.
dc.contributor.mitauthorWittrup, Karl Dane
dc.relation.journalJournal of Pharmaceutical Sciencesen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsMaass, Katie F.; Kulkarni, Chethana; Quadir, Mohiuddin A.; Hammond, Paula T.; Betts, Alison M.; Wittrup, Karl Daneen_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-0493-2863
dc.identifier.orcidhttps://orcid.org/0000-0002-5568-6455
dc.identifier.orcidhttps://orcid.org/0000-0003-2398-5896
dspace.mitauthor.errortrue
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record